CLINICAL trials on humans have begun in China for a potential coronavirus vaccine developed by German pharmaceutical group BioNTech with Chinese company Fosun Pharma, the companies said today.
Seventy-two participants have already received their first dose following approval for the phase 1 trial from Chinese regulatory authorities, BioNTech and Fosun Pharma said in a statement.